Literature DB >> 6411902

Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment.

W Löscher, H Nau.   

Abstract

Concentrations of valproic acid (VPA) and various metabolites were determined in plasma, cerebrospinal fluid and discrete brain areas in dogs after acute treatment with VPA as well as in rats during prolonged constant-rate application of the drug via osmotic minipumps. Highly sensitive gas chromatograph-mass spectrometer-computer methods were used for drug and metabolite analysis. Of several VPA metabolites present in plasma of dogs and rats only one could be found in the brain of both species, 2-propyl-2-pentenoic acid (2-en-VPA). Distribution of VPA and 2-en-VPA in the brain was rather homogenous, but during prolonged treatment accumulation of 2-en-VPA was found to occur in some brain regions. Determination of anticonvulsant potency of 2-en-VPA in mice indicated that the compound is about 1.3 times more potent than the parent drug when calculation is based on whole-brain concentrations. Administration of 2-en-VPA in a dog showed that pharmacokinetics of this substance are similar to those of VPA, although plasma protein binding of 2-en-VPA (97%) is much higher than of VPA. The results suggest that 2-en-VPA may contribute significantly to the anticonvulsant effect of (chronic) treatment with VPA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411902

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites.

Authors:  R E Dupuis; S N Lichtman; G M Pollack
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

2.  Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions.

Authors:  A S Luder; J K Parks; F Frerman; W D Parker
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

3.  Valproate metabolites in the rat brain--regional distribution in various brain areas.

Authors:  J Darius; F P Meyer; E Bergsträsser; E Ebermann; K Andreas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.441

Review 4.  Small molecule inhibitors of zinc-dependent histone deacetylases.

Authors:  Florence F Wagner; Michel Weїwer; Michael C Lewis; Edward B Holson
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 5.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 6.  Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as delta 2-valproate.

Authors:  H Nau; H Siemes
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

7.  Studies on 2-n-propyl-2(E)-pentenoate (delta 2(E)-valproate) in man.

Authors:  L Gram
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 8.  Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals.

Authors:  W Löscher
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

Review 9.  Influence of co-medication on the metabolism of valproate.

Authors:  F Pisani
Journal:  Pharm Weekbl Sci       Date:  1992-06-19

10.  Valproic acid downregulates RBP4 and elicits hypervitaminosis A-teratogenesis--a kinetic analysis on retinol/retinoic acid homeostatic system.

Authors:  Chao-Ming Chuang; Chi-Huang Chang; Hui-Er Wang; Kuan-Chou Chen; Chiung-Chi Peng; Chiu-Lan Hsieh; Robert Y Peng
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.